DBV Technologies shares drop 18.5% over one week, with the €1.57 support in sight
The Châtillon-based biotech is falling mid-session, in a Paris market trending lower amid a sharp correction in technology stocks. Its US approval application is progressing, while its financial position remains under close watch.
A stock below all its moving averages, down 18.7% over the week
DBV Technologies shares fell 2.98% to €1.72, in the lower part of the SBF 120, which lost 1.22%. The stock gave up 18.73% over seven days, although it still holds an 8.09% gain over one month, and it trades below its three moving averages.
The price is 7.86% below the MM50 and 37.80% below the MM200, a sign of a medium-term trend still pointing downward.
The RSI at 43 remains neutral, suggesting that the week's decline has not exhausted sellers. The €1.57 support, which the stock had approached in early November, now lies roughly 9% below the current price.
Cash position under watch and a US application under review
When the third-quarter accounts were published on October 28, 2026, the group reported a substantial doubt about its ability to continue as a going concern over the next twelve months. It states that it needs additional capital to finance its operations beyond the third quarter of 2027.
In return, the quarter's $64.5 million loss comes with an advanced regulatory file: the application for approval of the Viaskin Peanut patch in children aged 4 to 7 has been submitted to the FDA, with a decision expected in the fourth quarter of 2026 if priority review is granted.
Reported net short positions reach 3.59% of the share capital, spread across five funds, up 0.20 points over one month. This level shows that some institutional investors remain positioned against the stock, without signaling a massive loss of confidence.